Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Peaking beneath the surface of recent bevacizumab trials

Nature Reviews Clinical Oncology volume 8, pages 319–320 (2011)Cite this article

Subjects

Does targeting VEGF improve the lives of patients with metastatic breast cancer? Since the E2100 trial, there has been uncertainty about the benefit and toxicities of anti-VEGF therapy. By evaluating the RIBBON-1 trial results, we ask is such therapy failing, and are we considering all variables when scrutinizing the data?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Robert, N. J. et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252–1260 (2011).

    Article  CAS  PubMed  Google Scholar 

  2. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666–2676 (2007).

    Article  CAS  PubMed  Google Scholar 

  3. Miles, D. W. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28, 3239–3247 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Pazdur, R. Memorandum to the file BLA 125 085 Avastin (bevacizumab). FDA Center for Drug Evaluation and Research [online], (2010).

    Google Scholar 

  5. Gonzalez-Angulo, A. M. & Hortobagyi, G. N. Optimal schedule of paclitaxel: weekly is better. J. Clin. Oncol. 26, 1585–1587 (2008).

    Article  PubMed  Google Scholar 

  6. Burstein, H. J. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J. Clin. Oncol. 29, 1232–1235 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Miles, D. W. et al. Final overall survival results from the randomised, double-blind, placebo-controlled, phase III AVADO study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of locally recurrent or metastatic breast cancer [abstract 41]. Cancer Res. 69 (Suppl. 3), 495S (2009).

    Google Scholar 

  8. Colleoni, M. et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1–98 study. J. Clin. Oncol. 29, 1117–1124 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83–88 (2011).

    Article  CAS  PubMed  Google Scholar 

  10. Ranpura, V., Hapani, S. & Wu, S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 305, 487–494 (2011).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030–4009, TX, USA

    Ana M. Gonzalez-Angulo

  2. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030–4009, TX, USA

    Gabriel N. Hortobagyi

  3. Departments of Surgical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030–4009, TX, USA

    Lee M. Ellis

Authors
  1. Ana M. Gonzalez-Angulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lee M. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana M. Gonzalez-Angulo.

Ethics declarations

Competing interests

G. N. Hortobagyi serves as a consultant for Genentech Roche. L. M. Ellis serves as an ad hoc consultant for Bristol-Myers Squibb, Genentech Roche and Genomic Health. A. M. Gonzalez-Angulo declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonzalez-Angulo, A., Hortobagyi, G. & Ellis, L. Peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 8, 319–320 (2011). https://doi.org/10.1038/nrclinonc.2011.66

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.66

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer